FDA Reviews Berkshire Biomedical’s De Novo Application for Oral Rx System
July 7, 2025
Milestone Marks Critical Step Toward Bringing COPA to Market to Improve Access, Adherence and Outcomes in Opiod Use Disorder and Other Chronic Conditions Berkshire Biomedical Corporation, focused on developing